COVIDcast - Tocilizumab

We interrupt our normal FOAMcast episodes to bring you updates from COVID-19. *Our understanding of COVID-19 is rapidly developing and this may be out of date in days/weeks. So, check back for updates/fact check what you hear* Monoclonal antibodies have received significant attention over the past month and we previously podcasted on antibodies that target SARS-CoV-2. In this episode, we review several recent studies on a different "mab", tocilizumab,  which targets inflammation mediated by interleukin-6 that is overly ramped up.  We review: Stone et al  ( RCT) Hermine et al (RCT) Salvarani et al. (RCT) STOP-COVID (observational) Show notes (references/graphics): FOAMcast.org Thanks for listening, Lauren Westafer and Jeremy Faust

Om Podcasten

We believe in the educational merits of Free Open Access Medical education (FOAM), which includes podcasts, blogs, articles on PubMed Central, conferences streamed for free and more. As a result, we would like to encourage others to move beyond quoting podcasts and into the realm of tying “cutting edge” FOAM to the core content. We’ll provide some review and references for listeners to go read. Why, indeed, should we FOAM it alone when FOAM can inspire us to go, read, think, and be excellent?